You are here

Article Text

Article menu
Download PDFPDF
Scientific letters
Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease
  1. T Eizawa1,
  2. U Ikeda2,
  3. Y Murakami1,
  4. K Matsui1,
  5. T Yoshioka2,
  6. M Takahashi2,
  7. K Muroi3,
  8. K Shimada1
  1. 1Divisions of Cardiovascular Medicine, Jichi Medical School, Tochigi, Japan
  2. 2Department of Organ Regeneration, Shinshu University Graduate School of Medicine, Matsumoto, Japan
  3. 3Cell Transplantation and Transfusion, Jichi Medical School
  1. Correspondence to:
    Dr Uichi Ikeda
    Department of Organ Regeneration, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan; uikedasch.md.shinshu-u.ac.jp

https://doi.org/10.1136/hrt.2002.008144

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The bone marrow derived endothelial progenitor cells (EPCs) are considered to originate from haematopoietic stem cells, which are positive for CD34.1 Human CD34 expressing cells (CD34+ cells) injected into nude mice and rats undergoing neovascularisation caused by hindlimb ischaemia are incorporated into the neovasculature and express endothelial antigens. We recently reported that transplantation of autologous bone marrow cells, including CD34+ cells, improved ischaemia in patients with critical limb ischaemia.2 Moreover, increased neovascularisation by bone marrow derived CD34+ cells was shown to improve cardiac function.

    Recently, a mobilisation of EPCs into circulation from bone marrow was reported in patients with acute myocardial infarction and acute coronary syndrome,3,4 but little is known about the regulation of EPC mobilisation in patients with stable coronary artery disease (CAD). In the present study, we investigated the number of circulating CD34+ cells in patients with CAD and the influence of atherosclerotic risk factors on this number.

    METHODS

    Thirty four patients (mean (SEM) age …

    View Full Text